Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospit...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

TheMotleyMonk Apr. 7 at 11:18 AM

$LXRX Not so hot off the press, but new... PS: Never believe Wainwrong. CITI probably is a better guesstimate of P/S. https://finance.yahoo.com/markets/stocks/articles/lexicon-pharmaceuticals-lxrx-story-shifting-001757979.html

0 · Reply

BullriderNkg Apr. 7 at 1:53 AM

$LXRX I'm hoping and thinking that LXRX,Debanne and Exton get a big deal done. Because seriously, we are getting close to 3 months since the FDA gave us approval to start Phase 3 for Pilavapadin. Time is a waisting!!!

0 · Reply

Anon_ymous1 Apr. 6 at 9:44 PM

$LXRX How i wish i discovered this one in the 0.30 levels and went all in, this right here is depressing short term.

0 · Reply

Dooright Apr. 6 at 8:49 PM

$LXRX Same shit, different day! 😖 🙄Doc C. 🤓

0 · Reply

gucag006 Apr. 6 at 7:51 PM

$LXRX Raymond Debbane has the foresight on Sotagliflozin, which turns out to be the biggest flop in his otherwise successful career. Exactly how big was that disaster as oppose to the other 2 SGLT drugs: Jardiance (empagliflozin) - Approved for T2D in Aug/14 - Approved for HFrEF in Aug/21 - Approved for HFpEF in Feb/22 - Total sales up to date: $27B for Boehringer Ingelheim/Eli Lilly Farxiga (dapagliflozin) - Approved for T2D in Jan/14 - Approved for HFrEF in May/20 - Approved for HFpEF in May/23 - Total sales up to date: $35B for AstraZeneca Sotagliflozin (Zynquista & Inpefa) - Partnered with Sanofi on 11/5/15 - Focus on T1D/HF due to limited runway in T2D - Received 1st CRL for T1D on 3/22/19 - Sanofi ended agreement on 9/9/19 (notified in July/19) - Approved for HF (Inpefa) in 5/26/23 - Received 2nd CRR for T1D on 12/2024 - Total sales up to date: $11.8M Again, RD has the foresight on LX9211 and LX9851, and Sotagliflozin has last chapters (HCM & T1D) to run. RD, your legacy, please make them happen!

2 · Reply

Hightower777 Apr. 6 at 7:46 PM

$LXRX Its gotten awfully quiet around here lately.

0 · Reply

UofMAlum Apr. 6 at 5:56 PM

$LXRX

0 · Reply

gucag006 Apr. 5 at 11:56 PM

$LXRX If you follow the company long enough you will know we get here not by design or as planned from the beginning, but by adaptation. We had a B$ deal with Sanofi to develop Sota for T2D/T1D/HF. Sanofi had cold feet and terminated the partnership agreement after handing over the clinical trials and paid a parting fees of $260M. T1D got approved by EMA but never commercialized. Then former CEO mess up the Inpefa/HF NDA and had to resubmit causing almost 1Y delay. They hired VP Garner from BMY and 00s of sales associated to commercialized Inpefa after its approval by FDA, but had to dismiss the whole team after a year with next-to-nothing sale. Then they hired Mike Exton and nailed the distribution deal with Viatris for Inpefa/HF ex-US/EU, followed by Novo development deal for LX9851. Inpefa is the best-in-class HF drug, but effectively blocked by its BP competitors, which prompted them to change course in seeking BP partners moving forward - not by design but necessity.

3 · Reply

BullriderNkg Apr. 5 at 4:10 PM

$LXRX To me LX-9851 is now a binary risk free event with no needed or money out. The event it works and we get perhaps $1.X Billion in a couple of years or it doesn't work and we will get a few more dollars in the over the year. Hopefully Exton executes something with Pilavapadin soon!

1 · Reply

Iman133 Apr. 5 at 3:16 PM

$LXRX

0 · Reply

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Mar 23, 2026, 7:30 AM EDT - 15 days ago

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Mar 11, 2026, 8:00 AM EDT - 27 days ago

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

Mar 5, 2026, 6:59 AM EST - 4 weeks ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 4:01 PM EST - 4 weeks ago

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Feb 26, 2026, 8:30 AM EST - 5 weeks ago

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Feb 6, 2026, 5:17 PM EST - 2 months ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 30, 2026, 2:50 AM EST - 2 months ago

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 29, 2026, 4:31 PM EST - 2 months ago

Lexicon Announces Proposed Public Offering of Common Stock

Jan 23, 2026, 8:30 AM EST - 2 months ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

Jan 21, 2026, 8:30 AM EST - 2 months ago

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Jan 20, 2026, 6:59 AM EST - 2 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

VTRS

Jan 12, 2026, 7:30 AM EST - 3 months ago

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 8:30 AM EST - 3 months ago

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Jan 7, 2026, 8:30 AM EST - 3 months ago

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 5, 2025, 8:30 AM EST - 4 months ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Nov 25, 2025, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 11, 2025, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Nov 8, 2025, 2:30 PM EST - 5 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 6, 2025, 7:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 4, 2025, 8:30 AM EST - 5 months ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Oct 30, 2025, 8:30 AM EDT - 5 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 14, 2025, 8:00 AM EDT - 6 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 6 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 7 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 7 months ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 8:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 8:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 7:30 AM EDT - 8 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 8 months ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 9 months ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 9 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 23, 2025, 8:00 AM EDT - 10 months ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 10 months ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

May 29, 2025, 8:00 AM EDT - 11 months ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 11 months ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 4:00 PM EDT - 11 months ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 11 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Crash This Month

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 10:09 AM EDT - 1 year ago

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

NVO

Mar 28, 2025, 9:02 AM EDT - 1 year ago

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

NVO

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Mar 7, 2025, 8:30 AM EST - 1 year ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

TheMotleyMonk Apr. 7 at 11:18 AM

0 · Reply

BullriderNkg Apr. 7 at 1:53 AM

0 · Reply

Anon_ymous1 Apr. 6 at 9:44 PM

$LXRX How i wish i discovered this one in the 0.30 levels and went all in, this right here is depressing short term.

0 · Reply

Dooright Apr. 6 at 8:49 PM

$LXRX Same shit, different day! 😖 🙄Doc C. 🤓

0 · Reply

gucag006 Apr. 6 at 7:51 PM

2 · Reply

Hightower777 Apr. 6 at 7:46 PM

$LXRX Its gotten awfully quiet around here lately.

0 · Reply

UofMAlum Apr. 6 at 5:56 PM

$LXRX

0 · Reply

gucag006 Apr. 5 at 11:56 PM

3 · Reply

BullriderNkg Apr. 5 at 4:10 PM

1 · Reply

Iman133 Apr. 5 at 3:16 PM

$LXRX

0 · Reply

MYFLAUT Apr. 5 at 11:02 AM

$LXRX

1 · Reply

Viking0919 Apr. 4 at 4:00 AM

$LXRX

1 · Reply

Robyurii Apr. 4 at 12:01 AM

$LXRX Still bullish, but not a lot to post on until we hear some news. Wishing you all the best life has to offer.

0 · Reply

Itinerant Apr. 3 at 5:44 PM

$LXRX I have said that I do not like the business model of LXRX. I make a point about this. The business model creates an additional layer between us, the shareholders and the company actually effecting commercialization. LXRX does not get all of the information about the development and commercialization of the technology that the client knows (eg Novo). Then LXRX may choose to not pass on to us what it gets. So, the structure may critically reduce business information to the shareholders compared to a normal business model. If there is bad news in the development of the tech, Novo (in my example) may be able to choose to limit the information provided to LXRX pursuant to its agreement, and then LXRX may further limit what it tells us pursuant to legal agreement and/or regulation. This puts the shareholders in the dark relative to a normal business model. Therefore, the stock will always trade cheaply. Risk has been elevated by the model. Some will say I am paranoid. JMO

3 · Reply

User123321 Apr. 3 at 3:25 PM

$LXRX The range on 4/2/25 was .43-.52 with a .50 closing price. Yesterday it closed at 1.59 and it up is up 218% one year later. Yes he’s the one that looks like an imbecile and not you Hemorrhoids. Be gone GTFOOH. Thank you!

1 · Reply

Danadroids Apr. 3 at 2:37 PM

$LXRX it's okay guys. Just keep huffing Atreus' year old farts and you'll be okay

1 · Reply

GenericPoster Apr. 2 at 8:31 PM

$LXRX Thanks for the link and this is AI’s (Gemini) assessment of this study:

1 · Reply

macrossluvsrobotech Apr. 2 at 8:12 PM

$LXRX $LLY $NVO PART 3 They licensed this because it complements their drugs, fixes the biggest patient complaints (muscle loss + rebound), and gives them a next-gen oral combo that could keep patients on therapy longer and looking/ feeling better. This isn’t theory – it’s in their own preclinical data and the reason they fast-tracked the Phase 1. Bottom line: ACSL5 isn’t competing with GLP-1… it’s the upgrade that solves the problems GLP-1 created. $LXRX just got the biggest validation in biotech – a $1B vote of confidence from the obesity kings themselves. Who’s still sleeping on this? 😎 https://www.fiercebiotech.com/biotech/novo-inks-1b-lexicon-obesity-deal-after-seeing-preclinical-prospect-shine-semaglutide

0 · Reply

macrossluvsrobotech Apr. 2 at 8:11 PM

$LXRX $LLY $NVO PART 2 It’s not another GLP-1 copycat. It’s a small-molecule pill that blocks an enzyme in your intestine called ACSL5. This activates the natural “ileal brake” – your body’s own built-in satiety system. Result? ✅ Your gut naturally pumps out more of its own GLP-1 + PYY (the real hormones) after meals ✅ You eat less without feeling starved ✅ Fat burning ramps up while preserving muscle (preclinical data shows it protects lean mass – the holy grail) ✅ Weight loss is cleaner and sticks – even after you stop other drugs Lexicon’s mouse studies proved it: LX9851 + semaglutide = more weight loss LX9851 prevented the rebound when semaglutide was stopped Better body composition, less fat rebound, no muscle shredding That’s exactly why Novo Nordisk paid up to $1 BILLION (with $75M upfront + milestones) for global rights to LX9851 in March 2025. Novo already owns the GLP-1 kingdom. They don’t need another me-too drug. https://www.fiercebiotech.com/biotech/novo-inks-1b-lexicon-obesity-deal-after-seeing-preclinical-prospect-shine-semaglutide

0 · Reply

macrossluvsrobotech Apr. 2 at 8:06 PM

$LXRX $LLY $NVO PART 1: 🚨 $LXRX ACSL5 BREAKDOWN for the Skeptics – Why Novo Just Dropped Up to $1 BILLION on LX9851 Hey StockTwits fam – especially the GLP-1 doubters and “this is just another hype” crew. Let’s cut through the noise with simple science. GLP-1 drugs (Ozempic, Wegovy, Mounjaro, etc.) work one way: they mimic a gut hormone to slam the brakes on appetite and slow your stomach. Great for quick weight loss… but the downsides hit hard: “Ozempic face” (sagging skin, looking older) Muscle wasting (15-25%+ of the weight you lose can be lean muscle) Bone density loss from rapid change And the killer – quick fat rebound the second you stop (most people regain within a year) That’s because GLP-1s don’t fix the underlying metabolic “switch” – they just override it temporarily. ACSL5 (LX9851) is a completely different biochemical pathway. https://www.fiercebiotech.com/biotech/novo-inks-1b-lexicon-obesity-deal-after-seeing-preclinical-prospect-shine-semaglutide

0 · Reply

macrossluvsrobotech Apr. 2 at 7:48 PM

$LXRX "bro" ACSL5 is not GLP1 , and Novo doled out 1Bil for it. "bro". Looks like making money is on healthy trajectory. Be wary of the muscle waster, is all. The bone degrader, and the quick fat bounce back glp1 is all I'm sayin. Just cuz you can pop it, vs inject it, doesn't take away all the side effects I just listed. THOSE SIDE EFFECTS ARE PRECISELY WHY $NVO HAS PREPPED THAT 1 BIL PACKAGE. GET A GRIP.

0 · Reply

Jas7235355 Apr. 2 at 7:46 PM

$LXRX Also there are many factors that can make this go down and as many to make it go up. When a drug goes up after 3 years and someone dies from it …that will also make it get pulled from market and stock crashes Some of us who have hundred of thousands in it have to believe this is a game changer also with a couple others in their pipeline.

0 · Reply

Market Cap	673.65M
Revenue (ttm)	49.80M
Net Income (ttm)	-50.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-101.08%
Debt to Equity Ratio	0.50

Volume	1,586,900
Avg Vol	2,932,724
Day's Range	N/A - N/A
Shares Out	423.68M
Stochastic %K	36%
Beta	0.94
Analysts	Sell
Price Target	$3.36